Meta-analysis of efficacy and safety of bevacizumab in the treatment of hereditary hemorrhagic telangiectasia epistaxis
Objective: A meta-analysis is conducted to evaluate the effectiveness and safety of bevacizumab in hereditary hemorrhagic telangiectasia (HHT) epistaxis.Method: Two researchers search PubMed, EMBASE and Web of Science databases from their inception until September 3th, 2023. The literature is read a...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-12-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1089847/full |
| _version_ | 1797393396208238592 |
|---|---|
| author | Huimin Chen Zhiping Zhang Xiaojuan Chen Chaoyu Wang Mingdi Chen Huizhao Liao Jinru Zhu Zhenzhen Zheng Riken Chen |
| author_facet | Huimin Chen Zhiping Zhang Xiaojuan Chen Chaoyu Wang Mingdi Chen Huizhao Liao Jinru Zhu Zhenzhen Zheng Riken Chen |
| author_sort | Huimin Chen |
| collection | DOAJ |
| description | Objective: A meta-analysis is conducted to evaluate the effectiveness and safety of bevacizumab in hereditary hemorrhagic telangiectasia (HHT) epistaxis.Method: Two researchers search PubMed, EMBASE and Web of Science databases from their inception until September 3th, 2023. The literature is read and screened, and valid data extracted, collated and analyzed. Its quality is then assessed using the Cochrane risk assessment scale. This study uses Endnote 9.3 software for literature management and RevMan 5.3.1 software for evaluation.Results: A total of 7 documents met the requirements, including a total of 359 patients, and the literature quality evaluation was grade B. The Meta-analysis results showed that:Bevacizumab reduces the Epistaxis Severity Score (ESS) in patients with HHT epistaxis compared with the control [WMD = −0.22,95%CI (−0.38, −0.05), p = 0.01]. However, there is no significant effect on duration of epistaxis [WMD = −15.59, 95%CI (−70.41,39.23), p = 0.58] and number of epistaxes [WMD = −1.27,95%CI (−10.23,7.70), p = 0.78] in patients with HHT epistaxis. In terms of adverse effects, there is no significant difference between the bevacizumab group and control group [OR = 1.36, 95% CI (0.54, 3.44), p = 0.52].Conclusion: Bevacizumab is superior to the control group in the treatment of HHT epistaxis, and adverse reactions are not further increased in the bevacizumab group than in the control group, suggesting that bevacizumab has clinical value in the treatment of HHT epistaxis. |
| first_indexed | 2024-03-09T00:02:54Z |
| format | Article |
| id | doaj.art-582c721e2fb94be98585e98159989361 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-03-09T00:02:54Z |
| publishDate | 2023-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-582c721e2fb94be98585e981599893612023-12-12T15:32:33ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122023-12-011410.3389/fphar.2023.10898471089847Meta-analysis of efficacy and safety of bevacizumab in the treatment of hereditary hemorrhagic telangiectasia epistaxisHuimin Chen0Zhiping Zhang1Xiaojuan Chen2Chaoyu Wang3Mingdi Chen4Huizhao Liao5Jinru Zhu6Zhenzhen Zheng7Riken Chen8The Second Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, ChinaThe People’s Hospital of JiangMen, Jiangmen Hospital, Southern Medical University, Jiangmen, ChinaSun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, ChinaTaishan Hospital of Traditional Chinese Medicine, Jiangmen, Guangdong, ChinaThe Second Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, ChinaState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, ChinaThe Second Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, ChinaThe Second Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, ChinaThe Second Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, ChinaObjective: A meta-analysis is conducted to evaluate the effectiveness and safety of bevacizumab in hereditary hemorrhagic telangiectasia (HHT) epistaxis.Method: Two researchers search PubMed, EMBASE and Web of Science databases from their inception until September 3th, 2023. The literature is read and screened, and valid data extracted, collated and analyzed. Its quality is then assessed using the Cochrane risk assessment scale. This study uses Endnote 9.3 software for literature management and RevMan 5.3.1 software for evaluation.Results: A total of 7 documents met the requirements, including a total of 359 patients, and the literature quality evaluation was grade B. The Meta-analysis results showed that:Bevacizumab reduces the Epistaxis Severity Score (ESS) in patients with HHT epistaxis compared with the control [WMD = −0.22,95%CI (−0.38, −0.05), p = 0.01]. However, there is no significant effect on duration of epistaxis [WMD = −15.59, 95%CI (−70.41,39.23), p = 0.58] and number of epistaxes [WMD = −1.27,95%CI (−10.23,7.70), p = 0.78] in patients with HHT epistaxis. In terms of adverse effects, there is no significant difference between the bevacizumab group and control group [OR = 1.36, 95% CI (0.54, 3.44), p = 0.52].Conclusion: Bevacizumab is superior to the control group in the treatment of HHT epistaxis, and adverse reactions are not further increased in the bevacizumab group than in the control group, suggesting that bevacizumab has clinical value in the treatment of HHT epistaxis.https://www.frontiersin.org/articles/10.3389/fphar.2023.1089847/fullbevacizumabhereditary hemorrhagic telangiectasia epistaxistreatmentefficacymeta-analysis |
| spellingShingle | Huimin Chen Zhiping Zhang Xiaojuan Chen Chaoyu Wang Mingdi Chen Huizhao Liao Jinru Zhu Zhenzhen Zheng Riken Chen Meta-analysis of efficacy and safety of bevacizumab in the treatment of hereditary hemorrhagic telangiectasia epistaxis Frontiers in Pharmacology bevacizumab hereditary hemorrhagic telangiectasia epistaxis treatment efficacy meta-analysis |
| title | Meta-analysis of efficacy and safety of bevacizumab in the treatment of hereditary hemorrhagic telangiectasia epistaxis |
| title_full | Meta-analysis of efficacy and safety of bevacizumab in the treatment of hereditary hemorrhagic telangiectasia epistaxis |
| title_fullStr | Meta-analysis of efficacy and safety of bevacizumab in the treatment of hereditary hemorrhagic telangiectasia epistaxis |
| title_full_unstemmed | Meta-analysis of efficacy and safety of bevacizumab in the treatment of hereditary hemorrhagic telangiectasia epistaxis |
| title_short | Meta-analysis of efficacy and safety of bevacizumab in the treatment of hereditary hemorrhagic telangiectasia epistaxis |
| title_sort | meta analysis of efficacy and safety of bevacizumab in the treatment of hereditary hemorrhagic telangiectasia epistaxis |
| topic | bevacizumab hereditary hemorrhagic telangiectasia epistaxis treatment efficacy meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1089847/full |
| work_keys_str_mv | AT huiminchen metaanalysisofefficacyandsafetyofbevacizumabinthetreatmentofhereditaryhemorrhagictelangiectasiaepistaxis AT zhipingzhang metaanalysisofefficacyandsafetyofbevacizumabinthetreatmentofhereditaryhemorrhagictelangiectasiaepistaxis AT xiaojuanchen metaanalysisofefficacyandsafetyofbevacizumabinthetreatmentofhereditaryhemorrhagictelangiectasiaepistaxis AT chaoyuwang metaanalysisofefficacyandsafetyofbevacizumabinthetreatmentofhereditaryhemorrhagictelangiectasiaepistaxis AT mingdichen metaanalysisofefficacyandsafetyofbevacizumabinthetreatmentofhereditaryhemorrhagictelangiectasiaepistaxis AT huizhaoliao metaanalysisofefficacyandsafetyofbevacizumabinthetreatmentofhereditaryhemorrhagictelangiectasiaepistaxis AT jinruzhu metaanalysisofefficacyandsafetyofbevacizumabinthetreatmentofhereditaryhemorrhagictelangiectasiaepistaxis AT zhenzhenzheng metaanalysisofefficacyandsafetyofbevacizumabinthetreatmentofhereditaryhemorrhagictelangiectasiaepistaxis AT rikenchen metaanalysisofefficacyandsafetyofbevacizumabinthetreatmentofhereditaryhemorrhagictelangiectasiaepistaxis |